NICE guidance (NG28) suggests considering GLP-1 receptor agonists as part of dual or triple therapy when BMI is 35 kg/m (or 32.5 kg/m in people of South Asian and related ethnic groups) and weight loss would benefit other obesity-related comorbidities, or when other glucose-lowering therapies are not suitable
Together, these factors compromise the mouths natural protective mechanisms, increasing susceptibility to enamel erosion, tooth sensitivity, and the progressive loss of tooth structure
This is firmly territory to discuss with your diabetes care team, the DKA risk is the price of entry
Gallbladder-related events occurred in 2.6% of semaglutide vs 1.2% of placebo participants
L-GT: Software, Writing review & editing
"They're going to have to look at every single thing and trim dollars everywhere they can." Pennsylvania was looking for cost-saving strategies even before the new federal tax-and-spending law, according to Brandon Cwalina, press secretary for the state's Department of Human Services